Gastrointestinal Considerations in Patients with Cardiovascular Disease Using Nonopioid Analgesics for Mild-to-Moderate Pain or Cardioprotection

American Journal of Cardiology

Volumn 97, Issue 9 SUPPL. 1, 2006, Pages 17-22

  Wilcox Jr , C Mel ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTACID AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; LUMIRACOXIB; MISOPROSTOL; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; PARACETAMOL; PROTON PUMP INHIBITOR; RANITIDINE; SALSALATE; TRAMADOL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INTESTINE ULCER; LOW DRUG DOSE; PAIN; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH DISEASE; STOMACH MUCOSA INJURY; STOMACH ULCER; UNSTABLE ANGINA PECTORIS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL HEMORRHAGE; HUMANS; PAIN; RISK FACTORS;

EID: 33646160425     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.02.019     Document Type: Article

References (52)

1. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
2. De Gaetano G., and Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk. a randomised trial in general practice. [published correction appears in Lancet 2001;357:1134]. Lancet 357 (2001) 89-95
3. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S., and HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
4. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial. randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1998) 233-241
5. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S., Gilliland J., and Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296 (1988) 313-316
6. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [published correction appears in BMJ 2002;324:141]. BMJ 324 (2002) 71-86
8. Bresalier R.S. Aspirin and the prevention of colorectal neoplasia. Gastroenterology 125 (2003) 1539-1548
9. Eidelman R.S., Hebert P.R., Weisman S.M., and Hennekens C.H. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163 (2003) 2006-2010
10. Hayden M., Pignone M., Phillips C., and Mulrow C. Aspirin for the primary prevention of cardiovascular events. a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136 (2002) 161-172
11. National Consumers League. 2003 over-the-counter pain medication study. Available at: http://www.nclnet.org/otcpain/harrisesummary.htm. Accessed November 11, 2004.
12. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs. a view from the ARAMIS database. Am J Ther 7 (2000) 115-121
13. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
14. Scheiman J.M. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 25 (1996) 279-298
15. Cryer B., and Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117 (1999) 17-25
16. Feldman M., Shewmake K., and Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 279 (2000) G1113-G1120
17. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. a report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 290 (1974) 1158-1162
18. Silvoso G.R., Ivey K.J., Butt J.H., Lockard O.O., Holt S.D., Sisk C., Baskin W.N., Mackercher P.A., and Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 91 (1979) 517-520
19. Graham D.Y., and Smith J.L. Aspirin and the stomach. Ann Intern Med 104 (1986) 390-398
20. O'Laughlin J.C., Hoftiezer J.W., and Ivey K.J. Effect of aspirin on the human stomach in normals. endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand J Gastroenterol Suppl 67 (1981) 211-214
21. Weil J., Colin-Jones D., Langman M., Lawson D., Logan R., Murphy M., Rawlins M., Vessey M., and Wainwright P. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
22. Peters R.J.G., Mehta S.R., Fox K.A.A., Zhao F., Lewis B.S., Kopecky S.L., Diaz R., Commerford P.J., Valentin V., Yusuf S., and Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
23. Slattery J., Warlow C.P., Shorrock C.J., and Langman M.J.S. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin. analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 37 (1995) 509-511
24. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin. meta-analysis. BMJ 321 (2000) 1183-1187
25. Serrano P., Lanas A., Arroyo M.T., and Ferreira I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 16 (2002) 1945-1953
26. Sørensen H.T., Mellemkjær L., Blot W.J., Nielsen G.L., Steffensen F.H., McLaughlin J.K., and Olsen J.H. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 95 (2000) 2218-2224
27. Ruffalo R.L., Jackson R.L., and Ofman J.J. The impact of NSAID selection on gastrointestinal injury and risk for cardiovascular events. identifying and treating patients at risk. Pharmacol Ther 27 (2002) 570-576
28. Ouellet M., and Percival M.D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophys 387 (2001) 273-280
29. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum 43 (2000) 1905-1915
30. Prescott L.F. Paracetamol. past, present, and future. Am J Ther 7 (2000) 143-147
31. Peura D.A., Lanza F.L., Gostout C.J., Foutch P.G., and American College of Gastroenterology Institute for Clinical Research and Education. Report of the American College of Gastroenterology Institute for Clinical Research and Education. Am J Gastroenterol 92 (1997) 924-928
32. Pincus T., Koch G.G., Sokka T., Lefkowith J., Wolfe F., Jordan J.M., Luta G., Callahan L.F., Wang X., Schwartz T., et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44 (2001) 1587-1598
33. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63 (2004) 901-907
34. Amadio Jr. P., and Cummings D.M. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res 34 (1983) 59-66
35. Miceli-Richard C., Le Bars M., Schmidely N., and Dougado M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 63 (2004) 923-930
36. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 7 (2000) 63-74
37. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
38. Hrachovec J.B., and Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. [letter]. JAMA 286 (2001) 2398
39. Wright J.M., Perry T.L., Bassett K.L., and Chambers G.K. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. [letter]. JAMA 286 (2001) 2398-2399
40. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C.J., and TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications. randomised controlled trial. Lancet 364 (2004) 665-674
41. Laine L., Maller E.S., Yu C., Quan H., and Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition. a double-blind trial. Gastroenterology 127 (2004) 395-402
42. Koch M., Dezi A., Ferrario F., and Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. a meta-analysis of randomized controlled clinical trials. Arch Intern Med 156 (1996) 2321-2332
43. Taha A.S., Hudson N., Hawkey C.J., Swannell A.J., Trye P.N., Cottrell J., Mann S.G., Simon T.J., Sturrock R.D., and Russell R.I. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334 (1996) 1435-1439
44. Cullen D., Bardhan K.D., Eisner M., Kogut D.G., Peacock R.A., Thomson J.M., and Hawkey C.J. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 12 (1998) 135-140
45. Hawkey C.J., Karrasch J.A., Szczepanski L., Walker D.G., Barkun A., Swannell A.J., Yeomans N.D., and Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 727-734
46. Yeomans N.D., Tulassay Z., Juhász L., Racz I., Howard J.M., van Rensburg C.J., Swannell A.J., Hawkey C.J., and Acid Suppression Trial. Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. a comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 719-726
47. Silverstein F.E., Graham D.Y., Senior J.R., Davies H.W., Struthers B.J., Bittman R.M., and Geis G.S. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
48. Graham D.Y., Agrawal N.M., Campbell D.R., Haber M.M., Collis C., Lukasik N.L., and Huang B. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2002) 169-175
49. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. a meta-analysis. Ann Intern Med 115 (1991) 787-796
50. Garcia Rodríguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
51. Dubois R.W., Melmed G.Y., Henning J.M., and Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19 (2004) 197-208
52. Fendrick A.M., and Garabedian-Ruffalo S.M. A clinician's guide to the selection of NSAID therapy. Pharmacol Ther 27 (2002) 579-580 582